{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T02:29:49Z","timestamp":1780367389616,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,23]]},"DOI":"10.7759\/cureus.74329","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T06:43:41Z","timestamp":1732430621000},"source":"Crossref","is-referenced-by-count":4,"title":["Comparative Efficacy and Long-Term Outcomes of Beta-Blockers Alone or in Combination With Angiotensin-Converting Enzyme (ACE) Inhibitors in Chronic Heart Failure: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Waleed","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamima A","family":"Nila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeb","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O","family":"Okello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Maqbool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muath M","family":"Dabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Nour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiyyah M","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazeela","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Anum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh","family":"Pervaiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Congestive Heart Failure","author":"Malik A","year":"2024","unstructured":"Malik A, Brito D, Vaqar S, Chhabra L. Congestive Heart Failure. StatPearls (ed): StatPearls Publishing, Treasure Island; 2024."},{"key":"ref2","article-title":"Heart Failure With Preserved Ejection Fraction (HFpEF)","author":"Golla MSG","year":"2024","unstructured":"Golla MSG, Shams P. Heart Failure With Preserved Ejection Fraction (HFpEF). StatPearls (ed): StatPearls Publishing, Treasure Island; 2024."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-007-0487-y","article-title":"Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?","volume":"96","author":"van der Horst IC","year":"2007","unstructured":"van der Horst IC, Voors AA, van Veldhuisen DJ. Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?. Clin Res Cardiol. 2007, 96:193-95. 10.1007\/s00392-007-0487-y","journal-title":"Clin Res Cardiol"},{"key":"ref4","article-title":"Angiotensin-Converting Enzyme Inhibitors (ACEI)","author":"Herman LL","year":"2024","unstructured":"Herman LL, Padala SA, Ahmed I, Bashir K. Angiotensin-Converting Enzyme Inhibitors (ACEI). StatPearls (ed): StatPearls Publishing, Treasure Island; 2024."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan M","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, et al.. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020, 396:121-8. 10.1016\/S0140-6736(20)30748-0","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1575","article-title":"Safety, tolerability and efficacy of rapid optimization, helped by NT-proBNP and GDF-15, of heart failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study","volume":"21","author":"Kimmoun A","year":"2019","unstructured":"Kimmoun A, Cotter G, Davison B, et al.. Safety, tolerability and efficacy of rapid optimization, helped by NT-proBNP and GDF-15, of heart failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. Eur J Heart Fail. 2019, 21:1459-67. 10.1002\/ejhf.1575","journal-title":"Eur J Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2259","article-title":"Effect of sacubitril\/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial","volume":"23","author":"Bhatt AS","year":"2021","unstructured":"Bhatt AS, Vaduganathan M, Claggett BL, et al.. Effect of sacubitril\/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM-HF trial. Eur J Heart Fail. 2021, 23:1518-24. 10.1002\/ejhf.2259","journal-title":"Eur J Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019238","article-title":"Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF","volume":"10","author":"Ehteshami-Afshar S","year":"2021","unstructured":"Ehteshami-Afshar S, Mooney L, Dewan P, et al.. Clinical characteristics and outcomes of patients with heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: insights from PARADIGM-HF. J Am Heart Assoc. 2021, 10:e019238. 10.1161\/JAHA.120.019238","journal-title":"J Am Heart Assoc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.1.42","article-title":"Mode of death in heart failure: findings from the ATLAS trial","volume":"89","author":"Poole-Wilson PA","year":"2003","unstructured":"Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JG, Massie BM, Ryd\u00e9n L. Mode of death in heart failure: findings from the ATLAS trial. Heart. 2003, 89:42-8. 10.1136\/heart.89.1.42","journal-title":"Heart"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.0640","article-title":"Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial","volume":"5","author":"Fiuzat M","year":"2020","unstructured":"Fiuzat M, Ezekowitz J, Alemayehu W, et al.. Assessment of limitations to optimization of guideline-directed medical therapy in heart failure from the GUIDE-IT trial. JAMA Cardiol. 2020, 5:757-64. 10.1001\/jamacardio.2020.0640","journal-title":"JAMA Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00185.x","article-title":"Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial","volume":"29","author":"Krum H","year":"2011","unstructured":"Krum H, van Veldhuisen DJ, Funck-Brentano C, et al.. Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial. Cardiovasc Ther. 2011, 29:89-98. 10.1111\/j.1755-5922.2010.00185.x","journal-title":"Cardiovasc Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu504","article-title":"Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial","volume":"36","author":"Sakata Y","year":"2015","unstructured":"Sakata Y, Shiba N, Takahashi J, et al.. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial. Eur Heart J. 2015, 36:915-23. 10.1093\/eurheartj\/ehu504","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2003.12.016","article-title":"Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III","volume":"6","author":"Willenheimer R","year":"2004","unstructured":"Willenheimer R, Erdmann E, Follath F, et al.. Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. Eur J Heart Fail. 2004, 6:493-500. 10.1016\/j.ejheart.2003.12.016","journal-title":"Eur J Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2003.12.019","article-title":"Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN)","volume":"6","author":"Komajda M","year":"2004","unstructured":"Komajda M, Lutiger B, Madeira H, et al.. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN). Eur J Heart Fail. 2004, 6:467-75. 10.1016\/j.ejheart.2003.12.019","journal-title":"Eur J Heart Fail"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfr051","article-title":"Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial","volume":"13","author":"Funck-Brentano C","year":"2011","unstructured":"Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, Follath F, Goulder M, Willenheimer R. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail. 2011, 13:765-72. 10.1093\/eurjhf\/hfr051","journal-title":"Eur J Heart Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-9842(00)00120-3","article-title":"Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril","volume":"2","author":"Sturm B","year":"2000","unstructured":"Sturm B, Pacher R, Strametz-Juranek J, Berger R, Frey B, Stanek B. Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. Eur J Heart Fail. 2000, 2:407-12. 10.1016\/s1388-9842(00)00120-3","journal-title":"Eur J Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46486","article-title":"Advancements in heart failure management: a comprehensive narrative review of emerging therapies","volume":"15","author":"Sapna F","year":"2023","unstructured":"Sapna F, Raveena F, Chandio M, et al.. Advancements in heart failure management: a comprehensive narrative review of emerging therapies. Cureus. 2023, 15:e46486. 10.7759\/cureus.46486","journal-title":"Cureus"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1054\/s1071-9164(03)00133-7","article-title":"A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS","volume":"9","author":"Domanski MJ","year":"2003","unstructured":"Domanski MJ, Krause-Steinrauf H, Massie BM, et al.. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003, 9:354-63. 10.1054\/s1071-9164(03)00133-7","journal-title":"J Card Fail"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00750.x","article-title":"Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status","volume":"160","author":"Ma TK","year":"2010","unstructured":"Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol. 2010, 160:1273-92. 10.1111\/j.1476-5381.2010.00750.x","journal-title":"Br J Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1263482","article-title":"Beta-blocker management in patients admitted for acute heart failure and reduced ejection fraction: a review and expert consensus opinion","volume":"10","author":"Schurtz G","year":"2023","unstructured":"Schurtz G, Mewton N, Lemesle G, et al.. Beta-blocker management in patients admitted for acute heart failure and reduced ejection fraction: a review and expert consensus opinion. Front Cardiovasc Med. 2023, 10:1263482. 10.3389\/fcvm.2023.1263482","journal-title":"Front Cardiovasc Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f55","article-title":"Benefits of \u03b2 blockers in patients with heart failure and reduced ejection fraction: network meta-analysis","volume":"346","author":"Chatterjee S","year":"2013","unstructured":"Chatterjee S, Biondi-Zoccai G, Abbate A, et al.. Benefits of \u03b2 blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013, 346:f55. 10.1136\/bmj.f55","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000504167","article-title":"Benefits and risks of continuing angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and mineralocorticoid receptor antagonists during hospitalizations for acute heart failure","volume":"10","author":"Oliveros E","year":"2020","unstructured":"Oliveros E, Oni ET, Shahzad A, Kluger AY, Lo KB, Rangaswami J, McCullough PA. Benefits and risks of continuing angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, and mineralocorticoid receptor antagonists during hospitalizations for acute heart failure. Cardiorenal Med. 2020, 10:69-84. 10.1159\/000504167","journal-title":"Cardiorenal Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07248-1","article-title":"The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases","volume":"37","author":"Strauss MH","year":"2023","unstructured":"Strauss MH, Hall AS, Narkiewicz K. The combination of beta-blockers and ACE inhibitors across the spectrum of cardiovascular diseases. Cardiovasc Drugs Ther. 2023, 37:757-70. 10.1007\/s10557-021-07248-1","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.10.018","article-title":"Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care?","volume":"7","author":"Sharma A","year":"2022","unstructured":"Sharma A, Verma S, Bhatt DL, et al.. Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care?. JACC Basic Transl Sci. 2022, 7:504-17. 10.1016\/j.jacbts.2021.10.018","journal-title":"JACC Basic Transl Sci"}],"updated-by":[{"DOI":"10.7759\/cureus.r189","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"record-id":"67717"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/307226-comparative-efficacy-and-long-term-outcomes-of-beta-blockers-alone-or-in-combination-with-angiotensin-converting-enzyme-ace-inhibitors-in-chronic-heart-failure-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T06:43:44Z","timestamp":1732430624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/307226-comparative-efficacy-and-long-term-outcomes-of-beta-blockers-alone-or-in-combination-with-angiotensin-converting-enzyme-ace-inhibitors-in-chronic-heart-failure-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.74329","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,23]]}}}